SCHEDULE: FMR LLC Discloses 5.5% Stake in Zevra Therapeutics

FMR LLC, along with Abigail P. Johnson, has reported beneficial ownership of 5.5% of Zevra Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of Zevra Therapeutics Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially owned 3,211,876.51 shares, representing 5.5% of the class of securities.
• FMR LLC, organized in Delaware, is classified as a holding company (HC).
• Abigail P. Johnson, a U.S. citizen, is classified as an investment advisor (IA).
• The filing indicates that while FMR LLC has sole voting power over 3,194,804 shares, the aggregate beneficial ownership is 3,211,876.51 shares with sole dispositive power.
• The filing also notes that other persons may have the right to receive or direct the sale of these securities, but no single other person's interest exceeds five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership by a major financial institution and does not provide new operational or financial performance information about Zevra Therapeutics.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in Zevra Therapeutics.
• The reporting persons hold sole dispositive power over the reported shares, suggesting direct control over investment decisions.
• The filing is made under Rule 13d-1(b), suggesting a passive investment approach rather than an attempt to control the company.

Negatives

• The filing does not provide specific details on the acquisition cost or strategy behind the investment.
• The disclosure that 'one or more other persons are known to have the right to receive or the power to direct the receipt of dividends' could imply a complex ownership structure or potential for future changes in beneficial ownership.

Risks

• The filing does not explicitly mention any risks associated with Zevra Therapeutics Inc. or the investment itself.
• Potential for future changes in beneficial ownership due to the involvement of 'one or more other persons' mentioned in Item 6.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Zevra Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment by large financial institutions. FMR LLC's filing suggests a significant, but not controlling, stake in Zevra Therapeutics, aligning with typical investment strategies of asset managers in the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor, which can be viewed positively for stability, but also indicates that FMR LLC is not seeking control.
• Management: The filing reinforces that FMR LLC's investment is in the ordinary course of business, not for control purposes.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Continued monitoring of Zevra Therapeutics Inc.'s operational and financial performance by FMR LLC and Abigail P. Johnson.
• Potential for future amendments to the Schedule 13G filing if beneficial ownership changes significantly.

Key Dates

Keywords

Zevra Therapeutics, Schedule 13G, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management